{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "77-year-old man presented with metastatic intrahepatic cholangiocarcinoma (ICC).",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C22.1",
              "label": "Intrahepatic bile duct carcinoma",
              "status": "active",
              "onset_date": null
            },
            {
              "code": "C79.8",
              "label": "Secondary malignant neoplasm of other specified sites",
              "status": "active",
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Six months prior to presentation, the patient was diagnosed with a 6-cm right liver mass and underwent surgical resection. Pathology revealed cholangiocarcinoma (CCA) with sarcomatoid features (stage T1bN0M0).",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C0007945",
              "label": "Cholangiocarcinoma",
              "status": "historical",
              "onset_date": null
            }
          ],
          "procedures": [
            {
              "name": "Surgical resection",
              "approach": null,
              "date": null,
              "location": "liver",
              "performed_by": null,
              "outcome": null
            }
          ],
          "imaging": [
            {
              "type": "Mass of liver",
              "body_part": "Liver",
              "modality": null,
              "finding": "6-cm right liver mass",
              "impression": null,
              "date": null
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "Relevant past medical history included use of rosuvastatin at 40 mg PO QD.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C1644953",
              "dosage": "40 mg",
              "frequency": "QD",
              "modality": "PO",
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "Genomic testing (Foundation One CDx) revealed a BRAF exon 15 p.V600E mutation along with CDKN2a loss, CDKN2b loss, PIK3CA H1047R, CDKN1A R48*, and PIM1 amplification.",
        "clinical_data": {
          "labs": [
            {
              "test": "BRAF exon 15 p.V600E mutation",
              "value": "positive",
              "unit": null,
              "flag": "abnormal",
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "CDKN2a loss",
              "value": "positive",
              "unit": null,
              "flag": "abnormal",
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "CDKN2b loss",
              "value": "positive",
              "unit": null,
              "flag": "abnormal",
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "PIK3CA H1047R",
              "value": "positive",
              "unit": null,
              "flag": "abnormal",
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "CDKN1A R48*",
              "value": "positive",
              "unit": null,
              "flag": "abnormal",
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "PIM1 amplification",
              "value": "positive",
              "unit": null,
              "flag": "abnormal",
              "reference_range": null,
              "timestamp": null
            }
          ]
        }
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "content": "Patient received adjuvant capecitabine, but it was discontinued after three cycles due to a drug-related rash.",
        "clinical_data": {
          "medications": [
            {
              "drug": "Capecitabine",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": "adjuvant"
            }
          ],
          "allergies": [
            {
              "substance": "Capecitabine",
              "reaction": "drug-related rash",
              "severity": null,
              "date_recorded": null
            }
          ]
        }
      }
    },
    {
      "id": "N6",
      "label": "Step 6",
      "customData": {
        "node_id": "F",
        "node_step_index": 5,
        "content": "Restaging positron emission tomography\u2013computed tomography revealed a 1.2-cm left upper lobe nodule. Biopsy confirmed metastatic disease.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Positron emission tomography-computed tomography",
              "body_part": "lung",
              "modality": "PET",
              "finding": "1.2-cm left upper lobe nodule"
            }
          ],
          "procedures": [
            {
              "name": "Biopsy",
              "location": "left upper lobe nodule",
              "outcome": "metastatic disease"
            }
          ],
          "diagnoses": [
            {
              "code": "Metastatic disease",
              "label": "Metastatic disease",
              "status": "active"
            }
          ]
        }
      }
    },
    {
      "id": "N7",
      "label": "Step 7",
      "customData": {
        "node_id": "G",
        "node_step_index": 6,
        "content": "Patient transitioned to gemcitabine, cisplatin, and abraxane and received five cycles, with a best response of progressive disease.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0016738",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C0008833",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C1645382",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ],
          "diagnoses": [
            {
              "code": null,
              "label": "progressive disease",
              "status": null,
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N8",
      "label": "Step 8",
      "customData": {
        "node_id": "H",
        "node_step_index": 7,
        "content": "Patient enrolled in the TAPUR trial based on his BRAF exon 15 p.V600E mutation and started on vemurafenib (960 mg PO twice daily [BID]) and cobimetinib (60 mg PO once daily [QD], 21 days on, 7 days off).",
        "clinical_data": {
          "medications": [
            {
              "drug": "Vemurafenib",
              "dosage": "960 mg",
              "frequency": "BID",
              "modality": "PO",
              "start_date": null,
              "end_date": null,
              "indication": "BRAF exon 15 p.V600E mutation"
            },
            {
              "drug": "Cobimetinib",
              "dosage": "60 mg",
              "frequency": "QD",
              "modality": "PO",
              "start_date": null,
              "end_date": null,
              "indication": "BRAF exon 15 p.V600E mutation"
            }
          ]
        }
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Patient previously underwent surgical resection of a 6-cm right liver mass, with pathology revealing cholangiocarcinoma (CCA) with sarcomatoid features (stage T1bN0M0)."
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Patient was on rosuvastatin at 40 mg PO QD."
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "Genomic testing (Foundation One CDx) revealed a BRAF exon 15 p.V600E mutation along with CDKN2a loss, CDKN2b loss, PIK3CA H1047R, CDKN1A R48*, and PIM1 amplification.",
        "transition_event": {
          "trigger_type": "lab_change",
          "trigger_entities": [
            "C0003900",
            "C0007222"
          ],
          "change_type": "addition",
          "target_domain": "lab"
        }
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "Patient received adjuvant capecitabine, but it was discontinued after three cycles due to a drug-related rash.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0007557"
          ],
          "change_type": "discontinuation",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N5",
      "to": "N6",
      "data": {
        "edge_id": "E_to_F",
        "branch_flag": true,
        "content": "Restaging positron emission tomography\u2013computed tomography revealed a 1.2-cm left upper lobe nodule. Biopsy confirmed metastatic disease.",
        "transition_event": {
          "trigger_type": "imaging",
          "trigger_entities": [],
          "change_type": "progression",
          "target_domain": "imaging"
        }
      }
    },
    {
      "from": "N6",
      "to": "N7",
      "data": {
        "edge_id": "F_to_G",
        "branch_flag": true,
        "content": "Patient transitioned to gemcitabine, cisplatin, and abraxane and received five cycles, with a best response of progressive disease.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0016738",
            "C0008833",
            "C1645382"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N7",
      "to": "N8",
      "data": {
        "edge_id": "G_to_H",
        "branch_flag": true,
        "content": "Patient enrolled in the TAPUR trial based on his BRAF exon 15 p.V600E mutation and started on vemurafenib (960 mg PO twice daily [BID]) and cobimetinib (60 mg PO once daily [QD], 21 days on, 7 days off).",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C1644953",
            "C1644953"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    }
  ]
}